Physician profile
Christopher Stewart
NPI 1548284441
$45,374.95
in general payments reported to CMS, 2019-2025
41 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $14K · 2021: $3,691 · 2022: $582 · 2023: $513 · 2024: $465 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $12,291.51 | 2019-2023 | Erleada |
| Ferring Pharmaceuticals INC. | $6,206.92 | 2019-2024 | Adstiladrin |
| Astellas Pharma US INC | $4,199.62 | 2019-2022 | |
| Foundation Medicine, INC. | $3,954.95 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,504.89 | 2019-2024 | |
| Integra Gpo, LLC | $3,499.41 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $3,300.04 | 2020-2021 | |
| Genzyme Corporation | $2,066.53 | 2019 | |
| Progenics Pharmaceuticals, INC. | $2,047.21 | 2020-2024 | |
| Blue Earth Diagnostics | $1,007.02 | 2019-2024 | |
| Pfizer INC. | $362.03 | 2019-2023 | |
| Dendreon Pharmaceuticals LLC | $359.49 | 2019-2023 | Provenge |
| Myriad Genetic Laboratories, INC. | $252.33 | 2020-2024 | Prolaris |
| Boston Scientific Corporation | $246.79 | 2019-2023 | Rezum Generator |
| Sun Pharmaceutical Industries INC. | $226.85 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.